Polish Journal of Pathology
2/2025 vol. 76
Artykuł oryginalny

Identification of metabolism regulators as diagnostic markers for ulcerative colitis and their correlation with immune infiltration

Qilong Duan 1
,
Peng Liu 1
,
Hualei Chen 2
,
Yuanyuan Ding 2
,
Xiaoming Xu 2
  1. Shandong Medical College, Jinan, China
  2. Department of Gastroenterology, Jining No. 1 People’s Hospital, Jining, China
Pol J Pathol 2025; 76 (2): 110-119
DOI: https://doi.org/10.5114/pjp.2025.153972
Data publikacji online: 2025/09/22
Plik artykułu
PJP-03200.pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
1. Gros B, Kaplan GG. Ulcerative Colitis in Adults: A Review. JAMA 2023; 330: 951-965.
2. Syed S, Boland BS, Bourke LT, et al. Challenges in IBD Re­search 2024: Precision Medicine. Inflamm Bowel Dis 2024; 30 (Suppl 2): S39-S54.
3. Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lan­cet 2023; 402: 571-584.
4. Honap S, Jairath V, Danese S, Peyrin-Biroulet L. Navigating the complexities of drug development for inflammatory bowel disease. Nat Rev Drug Discov 2024; 23: 546-562.
5. Neurath MF, Vieth M. Different levels of healing in inflamma­tory bowel diseases: mucosal, histological, transmural, barrier and complete healing. Gut 2023; 72: 2164-2183.
6. Honap S, Jairath V, Sands BE, Dulai PS, Danese S, Peyrin-Bir­oulet L. Acute severe ulcerative colitis trials: the past, the pres­ent and the future. Gut 2024; 73: 1763-1773.
7. Fang X, Ardehali H, Min J, Wang F. The molecular and meta­bolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol 2023; 20: 7-23.
8. Faqerah N, Walker D, Gerasimidis K. Review article: The com­plex interplay between diet and Escherichia coli in inflammatory bowel disease. Aliment Pharmacol Ther 2023; 58: 984-1004.
9. Guo J, Li L, Cai Y, Kang Y. The development of probiotics and prebiotics therapy to ulcerative colitis: a therapy that has gained considerable momentum. Cell Commun Signal 2024; 22: 268.
10. Yang Y, Xiao G, Cheng P, Zeng J, Liu Y. Protective Application of Chinese Herbal Compounds and Formulae in Intestinal Inflam­mation in Humans and Animals. Molecules 2023; 28: 6811.
11. Zhang X, Zhang B, Peng B, et al. Different Dose of Sucrose Consumption Divergently Influences Gut Microbiota and PPAR-γ/MAPK/NF-κB Pathway in DSS-Induced Colitis Mice. Nutrients 2022; 14: 2765.
12. Long D, Mao C, Huang Y, Xu Y, Zhu Y. Ferroptosis in ulcer­ative colitis: Potential mechanisms and promising therapeutic targets. Biomed Pharmacother 2024; 175: 116722.
13. Peng S, Shen L, Yu X, et al. The role of Nrf2 in the pathogen­esis and treatment of ulcerative colitis. Front Immunol 2023; 14: 1200111.
14. Li J, Luo X, Shiu PH, et al. Protective effects of Amauroderma rugosum on dextran sulfate sodium-induced ulcerative colitis through the regulation of macrophage polarization and sup­pression of oxidative stress. Biomed Pharmacother 2024; 176: 116901.
15. Bourgonje AR, Kloska D, Grochot-Przeczek A, Feelisch M, Cuadrado A, van Goor H Personalized redox medicine in in­flammatory bowel diseases: an emerging role for HIF-1alpha and NRF2 as therapeutic targets. Redox Biol 2023; 60: 102603.
16. He N, Chen K, Yu S, et al. Stachyose Exerts Anticolitis Efficacy by Re-balancing Treg/Th17 and Activating the Butyrate-De­rived PPARgamma Signaling Pathway. J Agric Food Chem 2024; 72: 12171-12183.
17. Wang Y, Li M, Zha A. mTOR promotes an inflammatory re­sponse through the HIF1 signaling pathway in ulcerative coli­tis. Int Immunopharmacol 2024; 134: 112217.
18. Riviere P, Li Wai Suen C, Chaparro M, De Cruz P, Spinelli A, Laharie D. Acute severe ulcerative colitis management: un­answered questions and latest insights. Lancet Gastroenterol Hepatol 2024; 9: 251-262.
19. Thorp EB, Karlstaedt A. Intersection of Immunology and Metab­olism in Myocardial Disease. Circ Res 2024; 134: 1824-1840.
20. Wang X, Zhang C, Zhao G, Yang K, Tao L. Obesity and lipid metabolism in the development of osteoporosis (Review). Int J Mol Med 2024; 54: 61.
21. Dankar R, Wehbi J, Refaat MM. Tailoring Treatment in Cardi­ovascular Diseases: The Role of Targeted Therapies. Pharma­ceutics 2024; 16: 461.
22. Yamaji T, Hanada K. Sphingolipid metabolism and interorga­nellar transport: localization of sphingolipid enzymes and lipid transfer proteins. Traffic 2015; 16: 101-122.
23. Bayoumy AB, Mulder CJJ, Ansari AR, et al. Uphill battle: In­novation of thiopurine therapy in global inflammatory bowel disease care. Indian J Gastroenterol 2024; 43: 36-47.
24. Shi F, Gao YS, Han SM, et al. Allulose mitigates chronic enteri­tis by reducing mitochondria dysfunction via regulating cathep­sin B production. Int Immunopharmacol 2024; 129: 111645.
25. Ge W, Yue M, Lin R, et al. PLA2G2A(+) cancer-associated fi­broblasts mediate pancreatic cancer immune escape via imped­ing antitumor immune response of CD8(+) cytotoxic T cells. Cancer Lett 2023; 558: 216095.
26. Huang X, Yang X, Zhang M, et al. SELENOI Functions as a Key Modulator of Ferroptosis Pathway in Colitis and Colorec­tal Cancer. Adv Sci (Weinh) 2024; 2024: e2404073.
27. Sasidharan K, Caddeo A, Jamialahmadi O, et al. IL32 down­regulation lowers triglycerides and type I collagen in di-line­age human primary liver organoids. Cell Rep Med 2024; 5: 101352.
28. Hatori S, Sakamaki K, Yokohori T, et al. Clinical Significance of PLA2G2A Expression in Gastric Cancer Patients who Re­ceive Gastrectomy and Adjuvant S-1. Anticancer Res 2021; 41: 3583-3588.
29. Fijneman RJ, Cormier RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. Front Biosci 2008; 13: 4144-4174.
30. Ding X, Yan F, Wang W, Qin J, Luo L. Integration of tran­scriptomics and metabolomics identify biomarkers of aberrant lipid metabolism in ulcerative colitis. Int Immunopharmacol 2024; 131: 111865.
31. Escudero-Hernández C, van Beelen Granlund A, Bruland T, et al. Transcriptomic Profiling of Collagenous Colitis Identifies Hallmarks of Nondestructive Inflammatory Bowel Disease. Cell Mol Gastroenterol Hepatol 2021; 12: 665-687.
32. Court MH, Hazarika S, Krishnaswamy S, Finel M, Williams JA. Novel polymorphic human UDP-glucuronosyltransferase 2A3: cloning, functional characterization of enzyme variants, comparative tissue expression, and gene induction. Mol Phar­macol 2008; 74: 744-754.
33. Wu H, Zhong W, Zhang R, et al. G-quadruplex-enhanced circular single-stranded DNA (G4-CSSD) adsorption of miR­NA to inhibit colon cancer progression. Cancer Med 2023; 12: 9774-9787.
34. Yang X, Li P, Zhuang J, et al. Identification of Molecular Tar­gets of Bile Acids Acting on Colorectal Cancer and Their Cor­relation with Immunity. Dig Dis Sci 2024; 69: 123-134.
35. Low END, Mokhtar NM, Wong Z, Raja Ali RA. Colonic Mu­cosal Transcriptomic Changes in Patients with Long-Duration Ulcerative Colitis Revealed Colitis-Associated Cancer Path­ways. J Crohns Colitis 2019; 13: 755-763.
36. Wu X, Liu P, Wang Q, Sun L, Wang Y. A prognostic model established using bile acid genes to predict the immunity and survival of patients with gastrointestinal cancer. Environ Toxi­col. 2024. doi: 10.1002/tox.24287.
37. Szuber N, Orazi A, Tefferi A. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diag­nosis, genetics, risk stratification, and management. Am J He­matol 2024; 99: 1360-1387.
38. Lang W, Luo Y, Wang L, et al. The der(1;7)(q10;p10) defin­ing a distinct profile from -7/del(7q) in myelodysplastic syn­dromes: A systematic review and meta-analysis. Cancer Med 2024; 13: e6890.
39. Chen W, Xu Z, Jiang J, et al. Identification of LPCAT1 as a key biomarker for Crohn's disease based on bioinformatics and machine learnings and experimental verification. Gene. 2024; 920: 148519.
40. Hu Y, Tang J, Xie Y, et al. Gegen Qinlian decoction amelio­rates TNBS-induced ulcerative colitis by regulating Th2/Th1 and Tregs/Th17 cells balance, inhibiting NLRP3 inflammas­ome activation and reshaping gut microbiota. J Ethnopharma­col 2024; 328: 117956.
41. Wang S, Su W, Wu X, Dong W. Restoring Treg/Th17 cell balance in ulcerative colitis through HRas silencing and MAPK pathway inhibition. Int Immunopharmacol 2024; 130: 111608.
Copyright: © 2025 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Udostępnij
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications